leisure time -WSS

leisure time

author：entertainment 2025-09-03 05:30:59 - browse：49

NEW ORLEANS — For some patients suffering with certain blood cancers, CAR-T therapy can offer the tantalizing chance to end their disease with a single treatment.

But the immunotherapy takes time to manufacture, and patients often have to wait weeks to actually receive an infusion once they’re eligible. For some patients with especially aggressive cancer, they can die while waiting for the therapy to arrive.

That’s spurred CAR-T manufacturers to find ways to speed up manufacturing. The industry is testing newer — and possibly better — CAR-T cells that can be made more quickly. Researchers working with Novartis presented Phase 1 clinical trial data Sunday on a new CAR-T cell made with a rapid manufacturing process at the annual American Society of Hematology meeting.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： David Sabatini, ex

WSS

Anthos stroke drug appears safer than common blood thinner

'Revelatory' study finds a smoking impact that remains after quitting

Surge of respiratory disease in China has likely explanation

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

PBM reforms clear House panel

Wikipedia

leisure time

entertainment

What does generative AI mean for health care? We asked experts

PBM reforms clear House panel

How to save PrEP access — and even expand it

For Medicare Advantage, Democrats want stronger protections around AI

ChatGPT in medicine: STAT answers readers' burning questions

Weight loss drug costs may need more research, senator suggests

Medicare proposal to cover medical devices draws a mixed reaction

Why medical students are struggling with mental health

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The dental labor crisis is a moment of opportunity

leisure time

BioAge raises $170M for combination therapy with Zepbound

Why did Pfizer dish out millions for a Super Bowl ad?

Gilead might be held responsible for not developing a drug

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Key House Republican on health care plans exit from Congress

Gilead might be held responsible for not developing a drug

explore

knowledge

knowledge

focus